Journal
ANTIVIRAL RESEARCH
Volume 133, Issue -, Pages 165-177Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.07.015
Keywords
Coronavirus; MERS-CoV; Spike protein; Vaccines; Therapeutics; Animal models
Categories
Funding
- National Natural Science Foundation of China (NSFC) [080501, 81461168030]
- China Ministry of Science and Technology National 973 Project [2015CB910500]
- Canadian Institutes of Health Research (CIHR)
- Chinese Academy of Sciences (CAS)
Ask authors/readers for more resources
The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was first reported in September 2012. Despite great efforts, licensed vaccines or therapeutics against MERS-CoV remain unavailable. The MERS-CoV spike (S) protein is an important viral antigen known to mediate host-receptor binding and virus entry, as well as induce robust humoral and cell-mediated responses in humans during infection. In this review, we highlight the importance of the S protein in the MERS-CoV life cycle, summarize recent advances in the development of vaccines and therapeutics based on the S protein, and discuss strategies that can be explored to develop new medical countermeasures against MERS-CoV. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available